Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...